Detection of M. tuberculosis Using Cartridge-Based Technology in Patients with Negative Sputum Microscopy Results in a Regional Laboratory
https://doi.org/10.58838/2075-1230-2024-102-2-36-42
Abstract
The objective: to evaluate results of M. tuberculosis detection and testing drug susceptibility to rifampicin using molecular genetic methods in tuberculosis patients with a negative sputum smear microscopy result.
Subjects and Methods. Pulmonary tuberculosis patients registered in Arkhangelsk Region from 2016 to 2020 were enrolled in the study; those patients were notified as new cases and relapses with a negative sputum smear microscopy result before treatment and had results of molecular genetic testing (MGT) (Xpert MTB/RIF MTB/RIF) and BACTEC MGIT 960 available.
Results. 479 people (40%) were registered as pulmonary tuberculosis cases with a negative sputum smear microscopy result. MGT was performed in 327 (68%) patients. A positive result of MGT was received in 120 (37%) patients, a positive result of BACTEC MGIT 960 was received in 165 (50%) people. Concordance of results was observed in 70% of cases. In 136 (41%) people, both tests did not detect Mycobacterium tuberculosis, in 95 (29%) both tests showed a positive result. Discrepancies between the results of two tests were observed in 30% of cases. In 71 (22%) cases, culture growth was observed in BACTEC MGIT 960 with negative results of MGT. In 8% of cases, DNA of Mycobacterium tuberculosis was detected, but there was no culture growth on the nutrient medium. 43/120 (36%) cases of resistance to rifampicin were detected. The median time from sputum collection to initiation of MDR-TB treatment based on sputum MGT results made 18 (IQR 10–29) days. Molecular genetic testing makes it possible to promptly detect the majority of TB patients with a negative sputum smear result, and reduce the time for drug susceptibility testing, which allows this testing to be used as the first test when examining for pulmonary TB.
About the Authors
P. I. Eliseev
Northern State Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
Platon I. Eliseev, Associate Professor of Phthisiopulmonology Department
51 Troitsky Ave., Arkhangelsk, 163069
Phone: + 7 (8182) 21-11-63
E. I. Nikishova
Northern State Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
Elena I. Nikishova, Professor of Phthisiopulmonology Department
51 Troitsky Ave., Arkhangelsk, 163069
Phone: + 7 (8182) 21-11-63
A. Yu. Krupskaya
Northern State Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
Anastasia Yu. Krupskaya, Assistant of Phthisiopulmonology Department
51 Troitsky Ave., Arkhangelsk, 163069
Phone: + 7 (8182) 21-11-63
V. I. Shtraukh
Northern State Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
Valeria I. Shtraukh, Resident Physician of Clinical Diagnostic Laboratory, Department of Clinical Biochemistry, Microbiology and Laboratory Diagnostics
51 Troitsky Ave., Arkhangelsk, 163069
Phone: + 7 (8182) 21-11-63
E. S. Khimova
Northern State Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
Elena S. Khimova, Assistant of Phthisiopulmonology Department
51 Troitsky Ave., Arkhangelsk, 163069
Phone: + 7 (8182) 21-11-63
A. O. Maryandyshev
Northern State Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
Andrey O. Maryandyshev, Correspondent Member of RAS, Professor, Head of Phthisiopulmonology Department
51 Troitsky Ave., Arkhangelsk, 163069
Phone: + 7 (8182) 21-11-63
References
1. Andreevskaya S.N., Smirnova T.G., Larionova E.E. et al. Comparison of XPERT MTB/RIF cartridge technology with microbiological methods for the detection of Mycobacterium tuberculosis and drug susceptibility testing. Tuberkulez i Sotsialno-Znachimye Zabolevaniya, 2013, no. 2, pp. 25-29. (In Russ.)
2. Borodulina E.A., Shubina A.T., Gerasimov A.N. et al. GX technologies for rapid diagnosis of tuberculosis in general healthcare network. Vestnik Sovremennoy Klinicheskoy Meditsiny, 2022, vol. 15, no. 1, pp. 7-16. (In Russ.)
3. Vasilyeva I.A., Balasanyants G.S., Borisov S.E. et al. Tuberkulez u vzroslykh. Federal klinicheskie rekomendatsii. [Tuberculosis in adults. Federal guidelines]. Moscow, 2022. Available: https://cr.minzdrav.gov.ru/recomend/16_2 Accessed December 23, 2023.
4. Guseynalieva N.V. Improved detection of tuberculosis in primary health care and its impact on the incidence. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 10, pp. 41-46. (In Russ.)
5. Eliseev P.I., Detjen A., Dacombe R. et al. Impact of molecular genetic methods on the initiation of chemotherapy in multiple drug resistant tuberculosis patients in Arkhangelsk Region. Tuberculosis and Lung Diseases, 2018, vol. 95, no. 12, pp. 10-17. (In Russ.)
6. Eliseev P.I., Detjen A., Dacombe R. et al. The use of molecular genetic diagnostic tests to improve MDR TB treatment outcomes in Arkhangelsk Region. Tuberculosis and Lung Diseases, 2021, vol. 99, no. 8, pp. 21-26. (In Russ.)
7. Eliseev P.I., Nikishova E.I., Gorina G.P. et al. Results of Genotype MTBDRPLUS and Bactec MGIT to test drug susceptibility of tuberculous mycobacteria. Tuberculosis and Lung Diseases, 2012, vol. 89, no. 6, pp. 31-34. (In Russ.)
8. Lapteva E.A., Kovalenko I.V., Burakevich O.I. et al. Diagnostic value of genexpert MTB/RIF assay for tuberculosis diagnosis compared to traditional methods. Vestnik Grodnenskogo Gosudarstvennogo Meditsinskogo Universiteta, 2023, vol. 21, no. 2, pp. 118-123. (In Russ.)
9. Samoylova A.G., Burakova M.V., Vasilyeva I.A. et al. The impact of express rifampicin susceptibility testing on chemotherapy efficiency in those suffering from multiple drug resistant tuberculosis. Tuberculosis and Lung Diseases, 2016, vol. 94, no. 9, pp. 18-23. (In Russ.)
10. Sevastyanova E.V., Chernousova L.N. Modern algorithms of microbiological diagnostics of tuberculosis. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 7, pp. 11-17. (In Russ.)
11. Chernousova L.N., Sevastyanova E.V., Larionova E.E. et al. Federalnye klinicheskie rekomendatsii po organizatsii i provedeniyu mikrobiologicheskoy i molekulyarno-geneticheskoy diagnostiki tuberkuleza. [Federal clinical recommendations in organization and implementation of microbiological and molecular-genetic diagnostics of tuberculosis]. 2015. Available: https://tub-spb.ru/wp-content/uploads/2020/10/rec8.pdf Accessed November 11, 2023.
12. Ergeshov A.E., Chernousova L.N., Andreevskaya S.N. New technologies for diagnosing drug-resistant tuberculosis. Vestnik Rossiiskoy Akademii Meditsinskikh Nauk, 2019, vol. 74, no. 6, pp. 413-422. (In Russ.)
13. Acuña-Villaorduña C., Orikiriza P., Nyehangane D. et al. Effect of previous treatment and sputum quality on diagnostic accuracy of Xpert® MTB/RIF. The International Journal Tuberculosis and Lung Diseases, 2017, vol. 21, no. 4, pp. 389-397.
14. Albert H., Nathavitharana R.R., Isaacs С. et al. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? European Respiratory Journal, 2016, vol. 48, no. 2, pp. 516-525.
15. Blakemore R., Story E., Helb D. et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. Journal of Clinical Microbiology, 2010, vol. 48, no. 7, pp. 2495-2501.
16. Floyd S., Klinkenberg E., de Haas P. et al. Optimising Xpert-Ultra and culture testing to reliably measure tuberculosis prevalence in the community: findings from surveys in Zambia and South Africa. BMJ Open, 2022, vol. 12, no. 6, pp. e058195.
17. Grimes D.A., Schulz K.F. Refining clinical diagnosis with likelihood ratios. The Lancet, 2005, vol. 365, no. 9469, pp. 1500-1505.
18. Reechaipichitkul W., Phetsuriyawong A., Chaimanee P., Ananta P. Diagnostic test of sputum Xpert MTB/RIF MTB/RIF for smear negative pulmonary tuberculosis. Southeast Asian J. Trop. Med. Public Health, 2016, vol. 47, no. 3, pp. 457-466.
19. Salman H., Rusch-Gerdes S. MGIT Procedure Manual For BACTEC™ MGIT 960™ TB System. 2006.
20. Shi J., Dong W., Ma Y. et al. Xpert MTB/RIF MTB/RIF outperforms mycobacterial culture in detecting mycobacterium tuberculosis from salivary sputum. BioMed Research International, 2018, no. 2018, pp. 1514381.
21. Steingart K.R., Schiller I., Horne D.J. et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews, 2014, no. 1, pp. CD009593.
22. World Health Organization. Global TB report. Geneva, World Health Organization, 2021. Available: https://apps.who.int/iris/handle/10665/346387 Accessed 10 May 2022
23. World Health Organization et al. WHO standard: universal access to rapid tuberculosis diagnostics. 2023.
24. World Health Organization. Updated: Xpert MTB/RIF implementation manual technical and operational “how-to”: practical considerations. Geneva, World Health Organization, 2014.
Review
For citations:
Eliseev P.I., Nikishova E.I., Krupskaya A.Yu., Shtraukh V.I., Khimova E.S., Maryandyshev A.O. Detection of M. tuberculosis Using Cartridge-Based Technology in Patients with Negative Sputum Microscopy Results in a Regional Laboratory. Tuberculosis and Lung Diseases. 2024;102(2):36-42. (In Russ.) https://doi.org/10.58838/2075-1230-2024-102-2-36-42
Views:
421
Email this article 